Venture Life Group PLC (LON:VLG)‘s stock had its “buy” rating reiterated by equities research analysts at Panmure Gordon in a research report issued on Wednesday. They presently have a GBX 128 ($1.67) price target on the stock. Panmure Gordon’s target price suggests a potential upside of 143.81% from the company’s previous close.

Separately, Beaufort Securities reissued a “speculative buy” rating on shares of Venture Life Group PLC in a report on Monday, August 1st.

Shares of Venture Life Group PLC (LON:VLG) opened at 52.00 on Wednesday. Venture Life Group PLC has a 52 week low of GBX 43.00 and a 52 week high of GBX 81.92. The stock has a 50 day moving average of GBX 51.65 and a 200 day moving average of GBX 56.47. The stock’s market cap is GBX 17.89 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/venture-life-group-plc-vlg-earns-buy-rating-from-panmure-gordon.html

About Venture Life Group PLC

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.